Abstract 524: SP-3164, a novel ikaros and aiolos molecular glue degrader with preclinical activity in non-Hodgkin lymphomas
Daniela Y. Santiesteban, Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center), Sheila H. DeWitt, Stephen Horrigan(Translational Genomics Research Institute), Nadeem Q. Mirza, V. Jacques(Centre National de la Recherche Scientifique), Aundrietta D. Duncan(Io Therapeutics (United States))
Cited by 1
Related Papers
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
|Nature Medicine|2023|226
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
|Blood Advances|2020|224
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
|Blood|2021|213
CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity
|Blood Advances|2021|146